The UK Medicines and Healthcare products Regulatory Agency (MHRA) said it will develop an AI protocol checker aimed at helping clinical trial sponsors align planned studies with regulatory expectations. The initiative targets the protocol quality and compliance step before execution, with the goal of reducing avoidable deviations. While the approach is positioned as a support tool for sponsors, it also points to broader regulators adopting algorithm-assisted review workflows. That could reduce friction for multi-site trials that often face protocol clarification cycles during governance and start-up. For biotech leaders, the development is an operational signal: regulatory technology is moving beyond submission portals into analytical checking of trial design artifacts.